• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Early ART therapy for HIV-1 linked to decreased transmission: The HPTN 052 trial

byMatthew GrowdonandShaidah Deghan, MSc. MD
September 1, 2016
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Individuals infected with HIV-1 who were randomized to receive antiretroviral therapy (ART) at trial enrollment had a 97% and 93% lower risk of transmitting the virus compared to those who were randomized to receive ART on a delayed basis (when CD4+ count fell below 25 or when there was AIDS-defining illness) at 1.7 and 5 years, respectively.

2. Eight cases of genetically linked viral transmission were linked either to failure of ART in index participant or to cases in which transmission occurred before virologic suppression had been achieved in the index participant.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Despite advances in the prevention and therapy of HIV infection, more than 2 million new HIV-1 infections were reported worldwide in 2014. The interim analysis from the HIV Prevention Trials Network (HPTN) 052 trial established the benefit of early ART in preventing HIV-1 transmission in serodiscordant couples. The original study involved 1763 index participants diagnosed with HIV-1 and their sexual partners; in those randomized to the early-ART group, participants initiated ART at trial enrollment, while in the delayed group, ART was initiated when the CD4+ counts fell below 250 or when there was development of an AIDS-defining illness. Following the interim analysis results at a median follow-up period of 1.7 years, remaining participants in the trial were offered ART and followed to completion of 5 years of follow-up. In this extended analysis, there was a sustained, statistically and clinically significant reduction in the rate of genetically linked HIV-1 transmission between serodiscordant couples in the early versus delayed ART groups. Additionally, the authors found that there were no linked infections when virologic suppression had been achieved in the index participant.

Click to read the study, published today in NEJM

Relevant Reading: Prevention of HIV-1 infection with early antiretroviral therapy

RELATED REPORTS

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

Safety of investigational vaccines against human immunodeficiency virus

#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons

In-Depth [randomized controlled trial]: This study reports the 5-year results from the HPTN trial, in which 886 HIV-positive participants started ART at enrollment, while 877 HIV-positive participants were randomized to a delayed treatment arm. Index participants were recruited at 13 sites in 9 countries and were determined to be HIV-positive. After the interim analysis showed that early ART prevented 96% of genetically linked infections, participants in the delayed treatment arm were offered treatment in order to maintain ethical equipoise; 83% and 96% of these participants were receiving ART at one year and trial completion, respectively. Across both groups, there were 78 partners with documented HIV infections during the course of the trial; viral linkage was established in 92% of these subjects. In the intention-to-treat analysis, early ART was associated with a 97% lower risk than delayed ART in the interim analysis (median follow-up 1.7 years) and 93% lower risk during the entire study period of 5 years. In a multivariate analysis, early ART was associated with a strongly decreased risk of transmission compared to delayed ART (HR 0.08, 95%CI 0.02-0.25); increased HIV-1 viral load, female gender of index participant, and lack of baseline condom use of 100% were all associated with an increased risk of transmission. In 8 cases of genetically linked partner infections, 4 occurred in cases in which transmission occurred before virologic suppression in the index partners, and the remaining 4 occurred after ART failed in the index participant.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antiretroviralhuman immunodeficiency virus (HIV)
Previous Post

Formoterol-budesonide combination therapy for asthma does not increase adverse events

Next Post

Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial

RelatedReports

Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

June 16, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Infectious Disease

Safety of investigational vaccines against human immunodeficiency virus

April 29, 2025
#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons
StudyGraphics

#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons

December 11, 2024
Kidney Transplantation from Donors with Human Immunodeficiency Virus (HIV) is  Non-inferior to Donors Without HIV
StudyGraphics

Kidney Transplantation from Donors with Human Immunodeficiency Virus (HIV) is Non-inferior to Donors Without HIV

October 24, 2024
Next Post
Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial

Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial

Reduced gestational weight gain with lifestyle intervention

Exercise associated with reduced risk of C-section

USPSTF recommends biennial screening mammography in 50 to 74 year-old women

2 Minute Medicine Rewind September 5, 2016

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abridge drafts pediatric notes so physicians stay with the kids, not the keyboard
  • AAV gene therapy shows durable benefit in hemophilia B
  • Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.